Enveric Biosciences Inc ENVB:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 1:24 PM EDT
0.1983quote price arrow down-0.0212 (-9.6583%)
Volume
496,922
52 week range
0.17 - 3.74
Loading...
  • Open0.2139
  • Day High0.2198
  • Day Low0.1983
  • Prev Close0.2195
  • 52 Week High3.74
  • 52 Week High Date09/10/21
  • 52 Week Low0.17
  • 52 Week Low Date05/12/22

Key Stats

  • Market Cap10.45M
  • Shares Out52.68M
  • 10 Day Average Volume2.08M
  • Dividend-
  • Dividend Yield-
  • Beta1.77
  • YTD % Change-77.78

KEY STATS

  • Open0.2139
  • Day High0.2198
  • Day Low0.1983
  • Prev Close0.2195
  • 52 Week High3.74
  • 52 Week High Date09/10/21
  • 52 Week Low0.17
  • 52 Week Low Date05/12/22
  • Market Cap10.45M
  • Shares Out52.68M
  • 10 Day Average Volume2.08M
  • Dividend-
  • Dividend Yield-
  • Beta1.77
  • YTD % Change-77.78

RATIOS/PROFITABILITY

  • EPS (TTM)-1.62
  • P/E (TTM)-0.12
  • Fwd P/E (NTM)-0.40
  • EBITDA (TTM)-25.288M
  • ROE (TTM)-381.31%
  • Revenue (TTM)0.00
  • Gross Margin (TTM)22.25%
  • Net Margin (TTM)-19.34%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date08/11/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Enveric Biosciences Inc

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Enveric Biosciences, Inc. is an early-development-stage biosciences company. The Company is developing next-generation mental health and oncology treatments using a clinical discovery platform to enable psychedelic-derived molecules for the mind and synthetic cannabinoids for the body. It is developing its product candidates that are focused on cannabinoids derived from non-hemp botanical sources, and synthetic materials containing no tetrahydrocannabinol (THC) in order to...
David Johnson
Executive Chairman of the Board
Joseph Tucker Ph.D.
Chief Executive Officer, Director
Avani Kanubaddi
President, Chief Operating Officer
Carter Ward CPA
Chief Financial Officer
Jillian Hagel Ph.D.
Chief Technology Officer
Address
4851 Tamiami Trail N, Suite 200
Naples, FL
34103
United States

Top Peers

SYMBOLLASTCHG%CHG
PLX
Protalix Biotherapeutics Inc
1.06-0.01-0.93%
ANGN
Angion Biomedica Corp
1.15-0.07-5.74%
CDTX
Cidara Therapeutics Inc
0.4701-0.0128-2.6507%
MTEM
Molecular Templates Inc
1.13-0.04-3.42%
ORGS
Orgenesis Inc
2.15+0.03+1.42%